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1. Introduction 
Cervical cancer is still one of the leading cancers worldwide (1), although there is a 
discrepancy between developed and developing countries. In developed countries, there is a 
continuous decline in incidence and mortality, whereas in developing countries, there is a 
more stable or even increasing pattern. The latter is more likely to be due to the lack of 
screening and infectious cofactors than to ethnic differences. Cervical cancer remains the 
only human malignancy that has been successfully reduced by medical intervention. 
Organised screening (OrS) for cervical cancer by the conventional Pap smear is the only 
means with proven efficacy of reducing the incidence and mortality of this disease in 
countries where it has been successfully implemented. According to the official statistics, the 
age standardized incidence rate of cervical cancer in Italy currently (2002) levels of at 
8.1/100.000 with a mortality rate of 2.2/100.000 (2). Italy  is another European country with 
no unified national screening programme, but each region has adopted a screening policy of 
its own. (3)Cervical cancer screening in Italy started as a spontaneous activity, with no 
national organization, which, not unexpectedly, led to incomplete population coverage. The 
Italian health system is managed by Italy’s 20 Regions (Figure 1).  
Since 1996, Italian national guidelines have recommended to Regions the implementation of 
organised screening programmes for cervical cancer. These recommendations, largely based 
on European guidelines, include personal invitations to women aged 25 to 64 years for a Pap 
smear every three years, a monitoring system, and quality assurance for each phase of the 
programme. Surveys designed to assess the level of implementation of organised 
programmes in Italy and to collect process indicators have been conducted by Italian Group 
for Cervical Screening since 1997 (4,5,6,7,8,9,10,11,12,13). Their results have been published 
by the Osservatorio Nazionale Screening (ONS),(National Centre for Screening Monitoring) 
since 2002. Since 1993 in Trentino province (North Italy) an Organized Screening (OrS) exist 
for women 25-65 aged. The target population comprises 146737 women. In the period 1993 – 
2006 the pap-smears of OrS were examined in the Institutes of Anatomic Pathology and 
Cytopathology of S.Chiara Hospital Trento and Rovereto Hospital. Since 2007 the 
Cytopathology Section of Institute of Anatomic Pathology of Rovereto Hospital have 
examined only pap-tests of Opportunistic Screening (OpS), i.e. left to the woman’s initiative. 
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OpS may be considered as all Pap-test performed outside an OrS program. For example, 
some women have Pap-test at their doctor’s office during their physical examination 
independently of personal letter invitation of OrS. In Italy the complete screening history of 
women diagnosed with invasive cervical cancer has been performed only in Friuli Venezia 
Giulia – North eastern Italy -.  In these region an OrS was initiated in 1999, targeting women 
aged 25 – 64 years, who are invited to have a Pap-test every 3 years. The screening histories 
of Cervical Intraepithelial Neoplasia (CIN)3 - squamous cell carcinoma in >65 years-old 
women may be made with study of OpS, because the OrS offers a free-of-charge Pap-test 
every 3 years to all women aged 25-64 years. In the present study we have examined the 
screening histories, treatment, human papillomavirus (HPV) detection of CIN3- invasive 
squamous cell carcinoma in >65 years-old women, diagnosed in the period 2007-2010 with 
opportunistic Pap-tests in the Cytopathology Section of Institute of Anatomic Pathology of 
Rovereto Hospital.  
 
Fig. 1. Italy’s regions 
2. Materials and methods 
In the period 2007-2010 the Cytopathology Section of Institute of Anatomic Pathology of 
Rovereto Hospital have been examined 28589 opportunistic Pap smears. The standard 
technique of conventional opportunistic Pap smears involves taking two samples (one from 
the endocervix with cytobrush and one from ectocervix with Ayre spatule) and  smearing 
the cytological materials on two slides. The cytological diagnosis was performed using the 
2001 Bethesda System (14). An experienced cytopathologist whose diagnostic experience 
exceeds 20 years have examined all abnormal smears and 10% of the normal smears 
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previously observed a senior cytotechnologist. Colposcopic and cervical biopsies were taken  
by an experienced colposcopist (in practice for more than 10 years) and review by a senior 
colposcopist as part of the routine. HPV genotyping by PCR  was performed in all 
histological specimens (biopsy, cone, hysterectomy) with diagnosis of low grade and high 
grade intraepithelial lesions and invasive cervical carcinoma. 
3. Results 
111 cases (0,38%) of CIN3-squamous cell carcinoma has been identified in 28589 
opportunistic Pap smears. The distribution of women for decades is reported in Table 1. 
Between the women >64 years-old with CIN3-squamous carcinoma cytological diagnosis all 
were > 70 years-old and were not invited to OrS because of age > 64 years. We have 
reported in Table 2 the age, histological diagnosis, treatment and HPV detection of 8 
patients over 70 years with CIN 3 squamous cell carcinoma cytological diagnosis.  
Total number 
opportunistic 
Pap-tests 
≤ 20 Years 
(percentage). 
21 – 40 Years 
(percentage). 
41 – 70 Years 
(percentage). 
 
> 70 Years 
(percentage). 
28.589 
892 
(3.2%) 
11240 (39.3%) 
14848 
(51.9%) 
 
1620 
(5.6%) 
Table 1. Opportunistic screening: decades of age of 28.589 women in the period 2007-2001 
 
Number 
patients 
Age Treatment 
Histological diagnosis 
(pT) 
HPV finding 
1 81 
Hysterectomy with 
bilateral salpingo-
oophorectomy 
CIN3 HPV16 
2 82 Cone biopsy CIN3 Negative 
3 71 Cone biopsy CIN3 HPV58 
4 79 
Cone biopsy + 
radiotherapy 
Keratinizing squamous 
cell carcinoma NOS 
Negative 
5 75 
Hysterectomy with 
bilateral salpingo-
oophorectomy 
Non keratinizing 
squamous cell carcinoma 
(pT1b1) 
Negative 
6 82 Biopsy 
Keratinizing squamous 
cell carcinoma NOS 
Negative 
7 72 biopsy + radiotherapy 
Keratinizing squamous 
cell carcinoma NOS 
HPV58 
8 75 
Hysterectomy with 
bilateral salpingo-
oophorectomy + 
radiotherapy 
Non keratinizing 
squamous cell carcinoma 
(pT1b1) 
Negative 
Table 2. Age, treatment, histological diagnosis, HPV detection in women over 70 years-old 
with CIN3-squamous cell carcinoma. NOS= not other specified 
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The Pap smear was performed by gynecologist to the woman’s initiative. In the Pap smear 
of keratinizing squamous cell carcinoma  the cells showed significant nuclear and 
cytoplasmic abnormalities, the later usually showing a marked deviation from normal cells 
of the same origin. The malignant  keratinized cells had a characteristic bright orange or 
occasionally yellow cytoplasm that was dense and lack the transparent qualities of normal 
squamous cells. The size of keratinized cancer cells may vary from very large, comparable 
with normal superficial cells, to small, about the size of small parabasal cells. Their shape 
varies from round or polyhedral to quite irregular and bizarre (Figure 2). 
 
Fig. 2. Cancer cells with elongated keratinized eosinophilic cytoplasm and hyperchromatic 
nuclei in necrotic and hemorrhagic background. (Papanicolaou 40X). 
The nuclei were usually large for the size of the cells. As is often the case in the presence of 
cytoplasmic keratinization, nuclear pyknosis and karyorrhexis may occur, conferring on the 
nucleus a dark appearance. “Tadpole” cells were present. They were elongated, club-shaped 
cells, with one board and one narrow end. The round or irregular hyperchromatic nucleus 
was eccentrically located within the larger area of the cytoplasm . The degree of cytoplasmic 
keratinization was variable. The spindly squamoid cells were an unusual finding in the Pap 
smear. These cells were narrow, elongated, and needle-shaped. Keratinization was not 
necessarily seen, the cytoplasm may be either eosinophilic or basophilic. The nuclei  were 
nearly always elongated and  hypercromatic (Figure 3). 
 
Fig. 3.  Spindly squamous cancer cells. Note the markedly hyperchromatic  nuclei and the 
cytoplasmic keratinization. (Papanicolaou 40X). 
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The squamous “pearls” was a very rare finding in Pap smear of squamous cell carcinoma. 
These were concentrically arranged clusters of being  squamous cells. The difference 
between the benign and malignant “pearls” was in the configuration of the nuclei which, in 
the cancerous pearl, are enlarged and hypercromatic. In  the Pap smears of non-keratinizing 
squamous cell carcinoma  the malignant cells were solitary or arranged in syncytia (Figure 
4) and show anisokaryosis. The nuclei were relatively large with unevenly distributed, 
coarsely granular chromatin and may have irregular nucleoli. The Pap smear of CIN-3 were 
characterised by cells with nuclear-to-cytoplasmatic ratio significantly increased. The 
cytoplasm remained well-defined resembling that of very immature metaplastic cells. 
Nuclei tended to be considerably hyperchromatic, and marked irregularities of nuclear 
envelope might be present. The cytological characteristics of menopause were found in the 
Pap smear with malignant cells (Figures 5-6) and CIN-3. 
 
Fig. 4. A cluster concentrically arranged of undifferentiated cancer cells  (Papanicolaou 40X). 
 
Fig. 5. Cellular pattern of advanced menopause: the cells are parabasal with filaments of 
nuclear material resulting from breakdown of nuclei. A cluster of undifferentiated cancer 
cells of invasive squamous carcinoma with dark hyperchromatic nuclei is found. 
(Papanicolaou 10X). 
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Fig. 6. Cellular pattern of intermediate menopause with cluster of neoplastic squamous cells 
containing hyperchromatic and irregular nuclei. (Papanicolaou 10X). 
The cytologic patterns of the advanced atrophic menopause were influenced by dryness of 
the genital tract and scarsity of recoverable cellular material. The predominant cell was of 
the size and the degree of maturity corresponding to the parabasal cells. Two main effects of 
dryness might be observed: one was the uniform enlargement of the cell accompanied by a 
characteristic uniform gray discoloration of the degenerated nucleus; the second was by 
nuclear pyknosis and karyorrhexis. In the smear material of the eosinophilic pyknotic type 
there might be a striking variation in cell size and shape. Some cells might be relatively 
large, approaching the size of superficial cells, whereas others were the size of small 
parabasal cells. Sheets of spindly cells with elongated cytoplasm and large, pale nuclei may 
make their appearance in cervical smears and sometimes might be difficult to interpret. 
Nuclear pyknosis may be quite striking and often simulates the hyperchromasia of cancer 
cells; one must search for evidence of karyorrhexis in the form of granules of nuclear 
material within the cytoplasm. In some instances of extreme dryness, the cells break up 
during the process of smearing and will appear as standards and filaments of blue- staining 
nuclear material. The endocervical columnar cells in smear of the cervics were usually scarse 
or absent. When observed , the endocervical cells were smaller than during the childbearing 
age, although their columnar configuration was  still preserved. The nuclei, although of 
normal size, may appear somewhat hypercromatic, and the cytoplasm was scanty, opaque, 
and shows no evidence of secretory activity except for an occasional vacuole. One Pap 
smear CIN-3 and one Pap smear of keratinizing squamous cell carcinoma cointained cells 
with koilocytotic changes (Figure 7). In the  biopsies of CIN-3 maturation ( including surface 
keratinization ) was absent or confined to the superficial third of the epithelium. Nuclear 
abnormalities were marked throughout most or all of the thickness of the epithelium. 
Mitotic figures were numerous and were  found at all levels if the epithelium. Abnormal 
mitoses were frequent. Focal koilocytosis was present in one case.  Keratinizing squamous 
cell carcinoma were histologically characterized by mature squamous cells arranged in 
irregularly shaped nests or cords that varied considerably in size. The most striking feature 
was the present of keratine pearl within the nests of neoplastic squamous epithelium 
(Figures 8 and 9). 
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Fig. 7. Cellular pattern of intermediate menopause with nuclear enlargement of parabasal 
cells. Superficial squamous cell with koilocytotic atypia is present. (Papanicolaou 10X). 
 
Fig. 8. Cone biopsy of keratinizing squamous invasive carcinoma of the cervix. Nests of  
keratinizing, markedly atypical squamous neoplastic cells are evident. (H&E 10X). 
 
Fig. 9. Cone biopsy of keratinizing squamous invasive carcinoma of the cervix. Nest of  
keratinizing, markedly atypical squamous neoplastic cells is surrounded by dense 
inflammatory infiltrate . (H&E 10X). 
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Individual squamous cells were large ,with abundant eosinophilic cytoplasm, and many 
showed individual cell keratinization. The cells were closely apposed and often had 
prominent intercellular bridges. The nuclei may be enlarged or pyknotic. Mitotic activity 
was relatively low compared with the other tumor types. 
The non-keratinizing tumors were composed of generally recognized polygonal squamous 
cells that might have individual cell keratinization and intercellular bridge but keratin 
pearls were absent (Figure 10). Cellular and nuclear pleomorphism was more obvious than 
in the well differentiated tumours, and mitotic figures were usually numerous. 
 
Fig. 10. Cone biopsy of non-keratinizing squamous invasive carcinoma of the cervix. The 
neoplasm is composed of nests of tumor cells with basaloid differentiation.(H&E 10X). 
4. Discussion 
In 1990 cervical cancer comprised 10% of cancers in women for a total of approximately 
470,000 cancer cases world-wide (15), representing the third most common cancer in females 
and the most common cancer in Sub-Saharan Africa., Central America and South Central 
Asia. Approximately 230,000 women die annually from cervical cancer and over 190,000 of 
these are from developing countries. Zimbawe and India stand out not only for their high 
incidence, but also  for an unfavourable incidence to mortality ratio. Some relatively high-
incidence countries can also be  found in Eastern and Central Europe (16).The incidence and 
mortality of invasive squamous cell cervical carcinoma have decreased dramatically in the 
United States over the last three decades. The incidence in the United States was 34/100,000 
in 1947, 15/100,000 in1970, and 12/100,000 in 1986 (17). Although the incidence was 
decreased in the United States before the implementation of mass cervical cancer screening 
programs, screening has had an additional major impact on both the incidence  and 
mortality (65,111). The significance of cytologic screening in reducing the incidence of 
cervical cancer is further underscored by comparing the 4.5/100,000 incidence per year in a 
screened population to the 29/100,000 incidence in an unscreened population(18). Both 
cohorts exhibited similar epidemiologic characteristics. In the United States, approximately 
half of the women who develop cervical cancer have not had a cervical smear in the 
preceding 3 years(19). According to the most recent global estimates, invasive squamous cell 
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carcinoma is the second most common cancer in women world-wide, with the exception of 
skin cancer. There are approximately  493,000 new cases of invasive cervical cancer 
worldwide and 274,000 women die of the disease annually (20). The highest rates are 
reported in Latin America, where cervical cancer accounts for half of all female cancers. The 
annual incidence of invasive cervical cancer in women between 30 and 50 years  of age in 
high-risk areas is 1/1,000. In developing countries throughout the world, cervical cancer is a 
major public health problem and is one of the leading causes of death (21). Recent increases 
in incidence and mortality rates have been observed in some Western countries including 
Canada, Great Britain, Sweden, and Norway (22,23,24,25). In the United States, there were 
12,800 new cases and 4,600 cervical cancer deaths in 2000 (26). The incidence among blacks 
and Hispanics is two times higher than among whites in the United States. Moreover, in a 
recent study, after adjusting for a number of demographic factors, age, Federation  of 
Gynecology and Obstetrics (FIGO) stage, other tumor characteristics, and treatment, black 
women had a higher mortality rate than white women, indicating that race is an 
independent predictor of cervical cancer survival (27). Socioeconomic, religious, sexual, 
obstetric, dietary factors, immunosuppression, smoking, and oral contraceptive intake have 
been studied in relation to cervical cancer. Studies suggest that dietary carotenoids and 
vitamin C have a protective effect against cervical cancer (28,29). The risk of cervical cancer 
is increased by the number of sexual partners, the age at which sexual intercourse is 
initiated, and the sexual promiscuity of the male partner. Husbands of women with cervical 
cancer have more sexual partners than husbands of controls (30). In a recent study, smokers 
had a two-fold excess risk of cancer, with the risk linked to smoking intensity and duration 
(31). The effect was most striking among women who had smoked continuously up to the 
time of cancer diagnosis and women who began smoking late in life, suggesting that 
smoking played a promotional role in cervical cancer rather than an initiating role. Long-
duration use of hormonal contraceptives is associated with an increased risk of cervical 
cancer, but the public health implications depend largely on the extent to which the 
association remains long after the use of the contraceptives has ceased (31). Invasive 
squamous cell carcinoma is uncommon before the age of 30 years. Half of the patients, 
however, are less than 50 years old (32). In the United States, 22 percent of all women with 
cervical cancer are under the age of 35 years (33), but most are between 45 and 55 years of 
age al the time of diagnosis. Cervical cancer, however, can occur at almost any age between 
17 and 90 years.  The majority of the patients present with intermittent painless vagina, 
bleeding, often first noted after sexual intercourse or douching. With advancing disease, 
bleeding may become continuous, and be accompanied by a malodorous discharge and 
pain. Pain is frequently referred in the flank or leg as a result of tumor invasion of the pelvic 
wall or sciatic nerve. A cervical biopsy is mandatory for diagnosis. Although sampling 
problems and incorrect  interpretation are partly responsible for false negative smears, 
necrosis and inflammation on the surface of the tumor may result in only an “atypical 
smear” that lacks obvious tumor cells. Consequently, the cervix that is abnormal by 
inspection or palpation is biopsied, even if the cytology smear is normal. In addition to 
biopsy of the ectocervix, an endocervical curettage Is performed as an integral part of the 
evaluation because invasive carcinoma, particularly adenocarcinoma, frequently involves 
the endocervical canal and may not be visible on the ectocervix. Cervical cancer is the most 
common gynecologic cancer to occur during pregnancy: about 3 lo 10 percent of cervical 
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cancers occur in pregnant women. In these women, 83 percent present with stage I disease 
(34).  Invasive cervical cancer can be divided in two major histological types: squamous cell 
carcinoma and adenocarcinoma. In terms of percentages, 80–85% of cases are squamous cell 
carcinoma, 10% are adenocarcinoma, and 3% are adenosquamous carcinoma and other rare 
tumours (35). HPV infection is the most common sexually transmitted disease, with more 
than 80% of the population infected at some time in their life. The main risk factor is 
undoubtedly genital infection with HPV.  HPV infections are found in almost all pre-
invasive lesions, so-called CIN and invasive squamous cell cancers (36). Based on the still-
rising figures of HPV infections, one could consider it to be one of the most prevalent 
sexually transmitted pathogen diseases worldwide (1). From an epidemiological point of 
view, an HPV infection meets the criteria as a causal agent for cervical cancer (37,38). 
Current epidemiological and fundamental data have confirmed infection with HPV to be 
the basic cause of the disease (37,38). Having sexual contact is the main source of HPV 
infection. It is estimated that for every three people who have sex with a HPV-positive 
person, two will develop an infection within the next few months (1-19). In the majority of 
cases (75%), the infection will be asymptomatic. The peak prevalence of genital HPV 
infections is soon after the onset of sexual activity in women. HPV deoxyribonucleic acid 
(DNA) persists for about 6–12 months in the genital tract and spontaneously disappears in 
the majority of patients until an infection with a new type occurs. A persistent infection is 
the most important risk factor for initiating malignant transformation in the cervical 
epithelium. The time from initial infection to pre-invasive and, ultimately, invasive disease 
appears to be at least 10–15 years (1). Based on their association with cervical cancer, 
genotypes of HPV are divided into low-risk and high-risk groups, according to their 
presence in malignant lesions of the cervix.  Functionally high risk HPV types infection 
contributes to carcinogenesis and tumour progression predominantly through the action of 
two viral oncogenes, E6 and E7. The coordinated expression of E6 and E7 has been town to 
transform rodent cells and immortalize primary human keratinocytes (39,49). The E6 and E7 
proteins of high-risk HPVs have been demonstrated to be able to associate with the products 
of p53 and retinoblastoma susceptibility (Rb) genes, respectively, and inactivate the 
functions of these tumour suppressor proteins (40,41). The E6 protein exerts rapid 
degradation of p53, in corporation with E6-associated protein (E6-AP), via ubiquitin-
mediated proteolysis pathway (42, 43). The E7 protein mediates the release of the E2F 
transcription factor from pRb-E2F complex (44). Mutational analysis of HPV 16 E6 protein 
revealed that a certain level of the activity to degrade p53 is required for E6 to manifest its 
transforming function (45). The p53 mutations are the most frequent genetic abnormalities 
found in a wide variety of human malignant tumours (46). Once DNA damage occurs, p53 
protein is induced and arrests cells in the G1 phase to enhance DNA repair (47), or triggers 
apoptosis following DNA damage (48). These functions of p53 protein are important to 
maintain the genomic integrity. Mutant p53 proteins are devoid of these functions, because 
they lose the ability of DNA contact or destabilize the structure of the core domain (49). In 
this way, once p53 is mutated, DNA damage is fixed and subsequent genetic rearrangement 
progress which may be putative mechanisms to initiate cancer. Thus far, exceptionally low 
prevalence (0-6%) of the p53 mutations had been documented in cervical carcinomas (50, 51, 
52, 53, 54). The p53 protein in cervical carcinoma is thought to be inactivated presumably 
due to complex formation with HPV E6 oncoprotein. Although Crook et al initially 
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postulated that p53 mutations were confined to the HPVnegative cervical carcinomas 
(55,56), several recent studies implicated that p53 mutation was a very rare event and the 
occurrence was not strictly correlated with HPV status in primary cervical carcinomas 
(50,51,52,53,54). It has been also shown that p53 mutants identified in the HPV-positive 
anogenital cancers exhibit increased resistance to HPV E6-directed degradation, suggesting 
that mutation of p53 may play a role in the progression of the HPV-positive cervical cancer 
(56). The p53 mutation has been found only in 0–6% of cervical carcinomas. In light of recent 
studies demonstrating that mutation of p53 gene was found in over 20% of the patients with 
vulvar carcinoma (57, 58), a disease of elderly women and a known HPV- related 
malignancy, Nakagawa et al (59) analysed mutation of the p53 gene in 46 women with 
cervical carcinomas at the age of 60 or more (mean; 71 years, range; 60–96 years). Of the 46 
patients, 41 had squamous cell carcinoma (keratinizing type, ten; large cell non-keratinizing 
type, 31) and five had adenocarcinoma (endocervical type, four; endometrioid type, one). 
On the basis of the FIGO criteria, 12 women had Stage I, 18 Stage II, 15 Stage III and 1 Stage 
IV. The presence of HPV and its type were analysed by polymerase chain reaction (PCR)-
based assay using the consensus primers for L1 region. Mutation of the p53 gene was 
analysed by PCR-based single-strand conformation polymorphism and DNA sequencing 
technique. Point mutation of the p53 gene was detected in 5 out of 46 (11%) cervical 
carcinomas: 1 of 17 (6%) samples associated with high-risk HPVs (HPV 16 and HPV 18) and 
4 of 27 samples (15%) with intermediate-risk HPVs, whereas no mutation was found in 2 
HPV negative cases. The mutated residues resided in the selective sequence known as a 
DNA-binding domain. The immunohistochemistry revealed the overexpression in cancer 
tissues positive for p53 mutation. All of the observed mutations of the p53 gene were 
transition type, suggesting that the mutation may be caused by endogenous mutagenesis. 
Although falling short of statistical significance reduces the strength of the conclusion, data 
presented by Nakagawa et al imply that p53 gene mutation, particularly along with 
intermediate risk HPV types, may constitute one pathogenetic factor in cervical carcinoma 
affecting elderly women. To clarify the age-related genetic events in cervical cancer in 
elderly (>65 years) women, Saito et al (60) have analyzed for HPV typing via polymerase 
chain reaction, the expression of p53 via immunohistochemical study, and clinical behaviour 
66 tissue specimens obtained from patients with stage Ib-IIb cervical carcinoma. Of this 
group, 50 women aged 64 years and younger were designated as the younger group (mean 
age 46.7), and 16 women aged 65 years and older were designated as the older group (mean 
age 67.6) The prevalence of HPV DNA was higher in the younger group than in the older 
group (84.0 vs. 50.0%) as was the detection rate of HPV 16 (44.0 vs. 6.3%). In contrast, HPV 
18, 33, 52, 58, were frequently detected in older patients. The positive rate of p53 
overexpression in the older group was similar to that in the younger group (46.7 vs. 48.8%). 
There was no significant difference in the incidence of lymph node metastasis, histology, 
and the distribution of clinical stage between the two groups. In elderly Japanese women 
with stage Ib-IIb, the association of HPV of types other than HPV 16 is suggested to 
influence the progression of cervical cancer.  The most common member of the high-risk 
group is HPV 16, which accounts for more than 60% of all cervical cancers. The high-risk 
types account for more than 95% of all cases of cervical cancer. One of the main differences 
between high- and low-risk types is the possibility of integration in the genome. 
Approximately 1percent of the high-risk HPV types and only 0.1% of the low-risk HPV 
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types will lead to the development of cervical cancer (61). In our case HPV 16 and HPV 58 
were detected in two cases of CIN3 and HPV 58 in one case of squamous cell carcinoma. In 
one case of CIN3 and in 4 cases of squamous cell carcinoma the HPV type has been not 
detected. Two hypotheses may be made. There is a subset of squamous cell carcinomas that 
is unrelated to HPV. Other hypothesis takes into account that  HPV 16 is only integrated in 
72 percent of all invasive cervical cancers(62). The finding of the absence of HPV 16 DNA 
integration in some carcinomas implies that integration is not always required for malignant 
progression, but does not exclude the importance of HPV integration in the initiation of 
cervical cancer. Hypothetically, after the development of a carcinoma, the abnormal clone 
could lose the viral DNA. HPV 18, on the other hand, shows 100 percent integration. The 
epidermal growth factor receptor (EGFR) represents a cell membrane receptor characterized 
by an extracellular ligand-binding domain and an intracellular domain with tyrosine 
activity involved in signal transduction. EGFR receptor ligands such as epidermal growth 
factor (EGF) and tumor growth factor > binding to EGFR lead to a cascade of cellular events 
that are responsible for DNA synthesis, cell proliferation, mutation, survival maturation, 
and apoptosis (63). Aberrant EGFR expression results in abnormal growth, inhibition of 
apoptosis, angiogenesis,and  the promotion of invasion/metastasis (64). EGFR 
overexpression has been observed in several malignancies (65). Cyclooxygenase (Cox) is the 
enzyme involved in the conversion of arachidonic acid to prostaglandins in the critical steps 
of tumor onset and progression. Two Cox isoforms have been characterized. Cox-1 is 
expressed constitutively in almost all tissues and serves homeostatic functions. Cox-2, which 
is highly inducible by growth factors, prostaglandins, and tumor promoters, plays a key role 
in inflammatory response (66). Cox-2 overexpression has been reported in many neoplasms; 
its overexpression is associated with carcinogenesis and is linked to proliferation, 
neoangiogenesis, high microvessel density, and inhibition of apoptosis (67). Some authors 
have also clarified that the aggressiveness of Cox-2 expression in different malignant 
neoplasms is due to the ability of this substance to modulate adhesion molecule and 
protease expression (68,69). To find information on invasive squamous cervical carcinoma in 
the elderly, Giordano et al ( 70) have analyzed 110 invasive squamous cervical carcinomas 
obtained from 2 groups of patients for HPV status by polymerase chain reaction study, for 
immunohistochemical EGFR, Cox-2 expression, and clinicopathologic features.  In this study 
64 women 60 years or younger were designated as the younger group and 46 who were 61 
years or older were designated as the older group. The HPV status and the expression of 
Cox-2 and EGFR in the younger and older women were compared and correlated with the 
grading, staging neoplasm, and lymph nodal status. Overall survival curves were drawn 
using Kaplan-Meier estimates and were compared using log-rank tests in the whole series of 
110 patients.  The number of neoplasms with higher staging was significantly greater than 
those in the younger women. The mortality was higher in the older group than in the 
younger patients. In the elderly, the presence of HPV DNA in 65% of cases, and in the 
absence of sexual activity, could be due to reactivation of latent HPV infection. In 
accordance with data provided by the literature, this finding demonstrated that HPV DNA 
can be detected in elderly women and can be associated with cervical carcinoma (59,71,72). 
Thus, it is possible that, in elderly women, HPV presence, in the absence of sexual activity, 
could be due to reactivation of latent HPV infection because of impairment of host 
immunologic response (73). The overexpression of Cox-2 in a number of cases was 
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significantly higher in the older group than in the younger group, but this immunoreactivity 
is not related to the staging, grading, EGFR expression, or to the presence of HPV. The 
simultaneous expression of Cox-2 and EGFR had a poor prognostic significance, showing 
lower survival rates than cases without this immunoreactivity. On multivariate analysis, 
Cox-2 and EGFR immunopositivity did not reveal any correlation between these markers 
and prognosis probably because the number of cases considered was not particularly high. 
Inadequate immunologic control of HPV infection resulting in viral persistence is likely an 
important determinant of risk of progression to cervical neoplastic disease. Previous studies 
have provided evidence supporting this view. Higher prevalence of HPV infection is 
observed in HIV-infected individuals (74, 75). Studies have also reported associations 
between deregulation of cytokine production and impairment of CD4+ T cell–mediated 
immunity and cervical precancers (76,77,78,79). Finally, the consistent association observed 
between HLA alleles and cervical neoplasia argue for a role of the host immune response to 
HPV in cervical cancer pathogenesis (80). Immunologic competence has been reported to 
decrease with aging (81-93).  Garcia Piňeres et al (72) examined the association between 
lymphoproliferative responses to antigens/mitogens and persistent HPV infection in 
women older than 45 years. Women included in this study were participants in a 10,000-
woman population-based cohort study of cervical neoplasia in Costa Rica. Women older 
than 45 years and HPV DNA positive at a screening visit were selected as cases (n = 283). 
Garcia Piňeres et al  selected a comparably sized control group of HPV DNA–negative 
women, matched to cases on age and time since enrollment (n = 261). At an additional 
clinical visit, women were cytologically and virologically rescreened, and cervical and blood 
specimens were collected. Proliferative responses to phytohemagglutinin (PHA), influenza 
virus (Flu), and HPV16 virus-like particle (VLP) were lower among women with persistent 
HPV infection [median counts per minute (cpm): 72,849 for PHA, 1,241 for Flu, and 727 for 
VLP] than for the control group (median cpm: 107,049 for PHA, 2,111 for Flu, and 2,068 for 
VLP). The decreases were most profound in women with long-term persistence and were 
only observed for the oldest age group (≥65 years).  The results of this study indicate that an 
impairment in host immunologic responses is associated to persistent HPV infection. The 
fact that effects were evident for all studied stimuli is suggestive of a generalized effect.  
Since 1993, at least 7 studies have described the screening histories of women with invasive 
cervical cancer (95,96,97,98). The number of cases in these studies was between 469 and 
481All studies concluded that the lack of a cervical smear history is the major reason why 
the disease still occurs. The percentage of women with invasive cervical cancer that had no 
screening history varied between 28% in Connecticut, USA (99) and 54% for Maori women 
in New Zealand (100). This percentage strongly depends on the population coverage of 
screening. With a 100% coverage, the percentage will only include young women diagnosed 
before the starting age of the programme. In 2007 the almost 30%of the Italian population 
not included in organised programmes is partly the result of an implementation process still 
in progress in some Regions in Southern Italy, but mainly of a very limited or completely 
absent implementation in a few Regions in Northern Italy. In 2008 the extension of 
organised cervical cancer screening programmes in Italy had had a  target population  
13.8095.025 women, corresponding to 78,44% of Italian women aged 25-64 years vs 69% in 
2006.  During 2008, 39.69% of invites women were screened, vs 39.83% in the previous year. 
The results of single regions are not homogeneous(Table 3-13).  
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 2008 2007 2006 
Women 25-64 yrs 
included in the target 
population of 
organised 
programmes 
13.094.025 11.872.810 11.362.580 
Population 25-64 yrs 78,44 71,77 69,01 
Nominal extension 25,34(3.356.931/13.247.487) 25,58(3.055.353/11.943.507) 25,32(1.116.006/2.899.817) 
Compliance with 
invitation (%) 
39,69(1.332.376/3.356.931) 39,83(1.217.000/3.055.353) 38,49(1.116.006/2.899.817) 
NORTHERN ITALY
Women 25-64 yrs 
included in the target 
population of 
organised 
programmes 
5.210.405 4.942.788 4.911.641 
Population 25-64 yrs 68,42 65,42 65,09 
Nominal extension 29,5(1.541.010/5.222.404) 28,46(1.415.361/4.972.858) 27,17(1.341.812/4.938.269) 
Compliance with 
invitation (%) 
47,67(734.577/1.541.010) 46,93(664.344/1.415.361) 45,62(612.069/1.341.812) 
CENTRAL ITALY
Women 25-64 yrs 
included in the target 
population of 
organised 
programmes 
3.252.167 3.008.931 3.029340 
Population 25-64 yrs 98,09 91,86 93,95 
Nominal extension 26,52(890.868/3.359.359) 27,16(822.548/3.028.432) 26,84(814.208/3.033.546) 
Compliance with 
invitation (%) 
40,17(357.846/890.868) 40,23(330.925/822.548) 35,70(290.632/814.208) 
SOUTHERN ITALY AND ISLANDS
Women 25-64 yrs 
included in the target 
population of 
organised 
programmes 
4.631.453 3.921.091 3.421.599 
Population 25-64 yrs 80,38 68,65 60,09 
Nominal extension 19,83(925.053/4.665.724) 21,38(817.444/3.942.217) 21,38(743.797/3.479.433) 
Compliance with 
invitation (%) 
27,73(239.953/925.053) 27,12(221.731/817.444) 28,68(213.305/743.797) 
The data of Liguria region have not been reported. 
Legend: 
Nominal extension: percentage of the resident population aged 24-64 that is included in the target 
population of active organised programmes.  
PPV = Positive predictive value.  
DR = Detection rate.  
ASCUS = Atypical squamous cells of undetermined significance. 
CIN = Cervical Intraepithelial Neoplasia. 
Table 3. Extension of organised cervical cancer screening programmes in Italy. 
(http://www.osservatorionazionalescreening.it) 
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 ABRUZZO BASILICATA 
 2005 2006 2007 2008 2005 2006 2007 2008 
Nominal extension (%) 24,9 33,5 20,2 23,8 52 64,6 54,9 54,4 
Number of invitated women 87.398 118.054 73.981 88.974 90.013 111.808 96.613 95.476 
Compliance to invitation (%) 24,9 33,5 20,2 23,8 52,0 64,6 54,9 54,4 
Compliance with 
recommendation to repeat 
cytology% 
26,9 32,9 18 31,5 32,9 36,1 36,9 33,4 
Inadequate (%) 2,4 3,2 3,9  2,6 2,2 3 1,8 
Recommendation  to repeat 
cytology(%) 
2,8 3,7 4,3 4,5 2,1 2,1 4,3 2,4 
Compliance colposcopy with 
referral for ASCUS+ 
62,3 60,4 68,7 77,2 96,3 95,8 68,7 97,1 
DR° for lesions CIN2+ 
unadjusted 
2,7 2,5 3 4,2 1,2 1,1 1,1 0,9 
PPV for CIN2+ of ASCUS+ 
referred to colposcopy 
16,2 16,2 10,8 12,1 5,1 5,5 3,5 4,3 
Table 4. Organised cervical cancer screening programmes in Italy: value of some process 
indicators in Abruzzo and Basilicata regions between 2005-2008(National Centre for 
Screening Monitoring). (http://www.osservatorionazionalescreening.it) 
 CAMPANIA  EMILIA ROMAGNA 
 2005 2006 2007 2008  2005 2006 2007 2008 
Nominal extension (%) 24 14,9 17 18,5  27,8 31,4 30,8 33,4 
Number of invitated women 357.06 241.64 283.00 285.59  
332.6
5 
377.4
0 
379.16
2 
409.37
6 
Compliance to invitation (%) 24,0 14,9 17,0 18,5  27,8 31,4 30,8 33,4 
Compliance with 
recommendation to repeat 
cytology% 
16,8 26,1 27 27,2  57,1 50,8 56 56,5 
Inadequate citology (%) 2,1 2,6 2,6 2,7  1,5 1,7 2 2 
Recommendation  to repeat 
cytology(%) 
2,1 1,8 2,3 1,6  2,8 2,9 2,7 3,1 
Compliance colposcopy with 
referral for ASCUS+ 
75,3 63,9 40 63,4  89,1 83,2 85,9 88,8 
DR° for cytologyc lesions 
CIN2+ unadjusted 
1,6 1,3 1,4 1,5  3,6 3,8 4 4,4 
PPV for CIN2+ of ASCUS+ 
referred to colposcopy 
17,4 11,7 12,8 17,2  14,6 15,7 17,9 16,4 
Table 5. Organised cervical cancer screening programmes in Italy: value of some process 
indicators in Campania and Emilia Romagna regions between 2005-2008(National Centre for 
Screening Monitoring). (http://www.osservatorionazionalescreening.it) 
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 LAZIO LOMBARDIA 
 2005 2006 2007 2008 2005 2006 2007 2008 
Nominal extension (%) 13,7 22,1 24,2 23,3 24,9 27,1 29,7 25,7 
Number of invitated women 227.356303.896299.466360.688 136.919154.165164.979 198.728 
Compliance to invitation (%) 13,7 22,1 24,2 23,3 24,9 27,1 29,7 25,7 
Compliance with 
recommendation to repeat 
cytology% 
24,1 21,8 31,3 30,3 37,8 41,5 41 39,7 
Inadequate citology (%) 3,5 1,9 2,6 3,9 2,2 2,4 2,5 2,4 
Recommendation  to repeat 
cytology(%) 
2,9 2,4 2,7 2,7 1,5 1,4 2 1,9 
Compliance colposcopy with 
referral for ASCUS+ 
92 86,6 91,3 87,6 86,3 83,9 93 86 
DR° for cytologyc lesions 
CIN2+ unadjusted 
3,2 1,8 2,4 2,7 3,3 3 4 4 
PPV for CIN2+ of ASCUS+ 
referred to colposcopy 
14,9 10,2 12,3 12 27 21,5 22,3  
Table 6. Organised cervical cancer screening programmes in Italy: value of some process 
indicators in Lazio and Lombardia regions between 2005-2008(National Centre for Screening 
Monitoring). (http://www.osservatorionazionalescreening.it) 
 
 MOLISE  PIEMONTE 
 2005 2006 2007 2008  2005 2006 2007 2008 
Nominal extension (%) 59,6 18,6
Activated 
only for 4 
months 
21,5  29,7 27 30 31,8 
Number of invitated women 50 16  23  365.893 330.188 371.226 396.661 
Compliance to invitation (%) 59,6 18,6  21,5  29,7 27,0 30,0 31,8 
Compliance with 
recommendation to repeat 
cytology% 
21,7 14,4  19,3  42,4 42,9 43 44,7 
Inadequate citology (%) 6,3 6,3  12,1  2,8 2,6 3 3,2 
Recommendation  to repeat 
cytology(%) 
1,4 2,2  2,5  1,8 1,9 2 2 
Compliance colposcopy with 
referral for ASCUS+ 
61,5 37,1  63,1  90,7 91,6 92,2 90,5 
DR° for cytologyc lesions 
CIN2+ unadjusted 
1,5 0,62  1  2,1 2 2,2 2,3 
PPV for CIN2+ of ASCUS+ 
referred to colposcopy 
17,3 7,7  5,9  17,7 15,1 17,2 17,2 
Table 7. Organised cervical cancer screening programmes in Italy: value of some process 
indicators in Molise and Piemonte regions between 2005-2008(National Centre for Screening 
Monitoring). (http://www.osservatorionazionalescreening.it) 
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 TRENTINO  PUGLIA 
 2005 2006 2007 2008 2005 2006 2007 2008 
Nominal extension (%) 37 30 30,1 29,8   8 9,9 
Number of invitated women 52.305 43.455 45.104 44.852   41.094 105.599 
Compliance to invitation (%) 37,0 30,0 30,1 29,8   8,0 9,9 
Compliance with 
recommendation to repeat 
cytology% 
35,7 36,2 37 53,2   36,2 17,2 
Inadequate citology (%) 4,8 5,7 5,5 5   3 4 
Recommendation  to repeat 
cytology(%) 
1,5 1,3 1,3 1,2   4,4 1,2 
Compliance colposcopy with 
referral for ASCUS+ 
75,5 78,5 79 76   45,9 59,2 
DR° for cytologyc lesions CIN2+ 
unadjusted 
3,4 2,4 3,2 2,4   0,3 0,7 
PPV for CIN2+ of ASCUS+ 
referred to colposcopy 
29,6 23,9 31,5 28,3   1,6 9,2 
Table 8. Organised cervical cancer screening programmes in Italy: value of some process 
indicators in Trentino and Puglia regions between 2005-2008(National Centre for Screening 
Monitoring). (http://www.osservatorionazionalescreening.it) 
 SARDEGNA SICILIA 
 2005 2006 2007 2008 2005 2006 2007 2008 
Nominal extension (%) 27 24,6 20,4 26,4 26,1 24,6 21,1 21,2 
Number of invitated women 38.813 35.368 29.329 74.765 153.31 126.90 131.256 133.590 
Compliance to invitation (%) 27,0 24,6 20,4 26,4 26,1 24,6 21,1 21,2 
Compliance with 
recommendation to repeat 
cytology% 
24 23,7 31,4 33,7 19,03 29,1 25,4 19,7 
Inadequate citology (%) 6,3 5,8 6 6,1 3,4 3,5 0,3 1,9 
Recommendation  to repeat 
cytology(%) 
5,2 5,6 5,7 3 2,8 3,2 3,8 4 
Compliance colposcopy with 
referral for ASCUS+ 
82,6 93,1 88,2 91,1 70,5 73,4 81 83,9 
DR° for cytologyc lesions 
CIN2+ unadjusted 
3,7 4,5 5,7 4,2 1,9 2,6 3,1 3 
PPV for CIN2+ of ASCUS+ 
referred to colposcopy 
29,2 8,6 11,5 15,2 9,7 16,3 12,9 9,6 
Table 9. Organised cervical cancer screening programmes in Italy: value of some process 
indicators in Sardegna and Sicilia regions between 2005-2008(National Centre for Screening 
Monitoring). (http://www.osservatorionazionalescreening.it) 
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 TOSCANA UMBRIA 
 2005 2006 2007 2008 2005 2006 2007 2008 
Nominal extension (%) 28,7 29,8 31,3 29,9 27,3 29,3 23,5 31,5 
Number of invitated women 291.516 303.307 319.444 309.365 67.635 73.206 58.556 78.215 
Compliance to invitation (%) 28,7 29,8 31,3 29,9 27,3 29,3 23,5 31,5 
Compliance with 
recommendation to repeat 
cytology% 
44,1 46,6 48 49,6 44,4 47,1 58,2 47,5 
Inadequate citology (%) 2 2,1 1,8 1,5 1,7 3,4 1,3 2,3 
Recommendation  to repeat 
cytology(%) 
1,6 1,6 1,5 1,5 2 2 1,6 1,6 
Compliance colposcopy with 
referral for ASCUS+ 
78,5 77,6 81,3 82,7 68,3 70,7 66,1 78 
DR° for cytologyc lesions 
CIN2+ unadjusted 
2,6 2,9 2,8 3 3,3 4,2 2,4 4,2 
PPV for CIN2+ of ASCUS+ 
referred to colposcopy 
21,8 25,1 24,2 23,9 57,3 29,1 22,6 34,2 
Table 10. Organised cervical cancer screening programmes in Italy: value of some process 
indicators in Toscana and Umbria regions between 2005-2008(National Centre for Screening 
Monitoring). (http://www.osservatorionazionalescreening.it) 
 VALLE D'AOSTA  VENETO 
 2005 2006 2007 2008 2005 2006 2007 2008 
Nominal extension (%) 31,8 32,6 28 26,7 22,8 24,1 24,4 25,7 
Number of invitated women 11.490 11.486 9.728 9.478 305.925 315.619 321.37 346.4 
Compliance to invitation (%) 31,8 32,6 28,0 26,7 22,8 24,1 24,4 25,7 
Compliance with 
recommendation to repeat 
cytology% 
62 63,8 59,4 73,8 44,47 43,8 44,8 41,8 
Inadequate citology (%) 5,5 4,5 1 0,8 5,7 4,7 5,4 5,4 
Recommendation  to repeat 
cytology(%) 
3,4 4,5 2,4 1,6 2,8 2,8 3 3,1 
Compliance colposcopy with 
referral for ASCUS+ 
85 94,1 93,9 95,2 90,5 91,6 92,3 91,6 
DR° for cytologyc lesions CIN2+ 
unadjusted 
2,5 2,5 3,8 1,6 2,7 2,9 2,8 3,3 
PPV for CIN2+ of ASCUS+ 
referred to colposcopy 
12,2 12,9 20,8 13,9 12,8 13,3 13,1 14 
Table 11. Organised cervical cancer screening programmes in Italy: value of some process 
indicators in Valle D’Aosta and Veneto regions between 2005-2008(National Centre for 
Screening Monitoring). (http://www.osservatorionazionalescreening.it) 
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FRIULI VENEZIA GIULIA  MARCHE 
 2005 2006 2007 2008 2005 2006 2007 2008 
Nominal extension (%) 30 27,8 25,2  32,4 31,8 32,7  
Number of invitated women 98,619 90,948 86,085  145,35 134,79 140,03  
Compliance to invitation (%) 30,0 27,8 25,2  32,4 31,8 32,7  
Compliance with 
recommendation to repeat 
cytology% 
54,9 51,9 56,2  33 36,2 35,2  
Inadequate citology (%)  6,5 6   1,1 2  
Recommendation  to repeat 
cytology(%) 
2,3 2,2 2,1  1,9 1,8 2  
Compliance colposcopy with 
referral for ASCUS+ 
88,8 90,7 88  90,4 80 84,7  
DR° for cytologyc lesions CIN2+ 
unadjusted
    2,1 1.05 2,1  
PPV for CIN2+ of ASCUS+ 
referred to colposcopy
    26,4 12,1 17,1  
Table 12. Organised cervical cancer screening programmes in Italy: value of some process 
indicators in Friuli Venezia Giulia and Marche regions between 2005-2008(National Centre 
for Screening Monitoring). (http://www.osservatorionazionalescreening.it) 
 
ALTO ADIGE 
(SUDTIROL) 
 CALABRIA 
 2005 2006 2007 2008 2005 2006 2007 2008 
Nominal extension (%) 22,4 13,4 26,1  41,4 24,2 35,6  
Number of invitated women 32,194 18,542 37,699  21,619 94,105 162,16  
Compliance to invitation (%) 22,4 13,4 26,1  41,4 24,2 35,6  
Compliance with 
recommendation to repeat 
cytology% 
32,2 34 32,2  25 25 24,4  
Inadequate citology (%) 1,1 0,75 0,85   2,3 3,6  
Recommendation  to repeat 
cytology(%)
    0,6 2,2 2,7  
Compliance colposcopy with 
referral for ASCUS+ 
    71,4 75,5 81,7  
DR° for cytologyc lesions CIN2+ 
unadjusted 
    0,9 2.24 1,3  
PPV for CIN2+ of ASCUS+ 
referred to colposcopy
    25 9,5 6,3  
Table 13. Organised cervical cancer screening programmes in Italy: value of some process 
indicators in Alto Adige and Calabria regions between 2005-2008(National Centre for 
Screening Monitoring). (http://www.osservatorionazionalescreening.it) 
www.intechopen.com
Human Papillomavirus and Related Diseases 
– From Bench to Bedside – Research Aspects 
 
84
The main examined process indicators has been not reported in all the  regions. The 
distinction between  OpS and OS screening has not been done. In the literature numerous 
studies has been reported the recommendations and the results of cervical cancer 
screening(100-101-102-103-104). With regard to screening histories  of invasive cervical 
carcinoma, in Italy has been not published studies with exception of OrS programme of 
Friuli Venezia Giulia. Zucchetto et al (105) have examined the screening histories of 438 
women with invasive cervical cancer diagnosed in Friuli Venezia-Giulia between 1999 and 
2005. 82 cases (49.7%) were found in >65 years-old women. 165 (37.7%) women were not 
screening. 69 (15.8%) women were not invited to OrS because of age >64 years old. 
Histological type and HPV detection of invasive cervical cancers has been reported. The 
study of Zucchetto et al (105) shows that the lack of screening among older women and of 
compliance with organized programs among women in the target population are the main 
limitation in cervical cancer secondary prevention.  The results of Zucchetto et al (105) are in 
agreement with research conducted in northen Europe. Bos et al (106) have analized the 
screening history of 3.175 women with invasive cervical cancer diagnosed in the years 1994-
1997 in the Netherland. 57% of 3175 women with invasive cervical cancer had no previous 
smears. Given the high proportion of women with invasive cervical cancer older than 64 
years at diagnosis, the possibility of inviting them to have at least one Pap smear in life after 
64 years should be taken in consideration. In according to American Cancer Society 
Guidelines for the early detection of cancer and the guidelines of other national regional 
screening programme, women 70 years of age or older who have had 3 or more normal Pap-
test in a know and no abnormal Pap-test results in the last 10 years may choose to stop 
having Pap-test. But according to National Cervical Screening program the current policy of 
screening women of New Zealand is to continue organized regular screening until aged 69 
years with pap test every three years if the women have ever been sexually active remain in 
place. The present study should be support the screening policy to perform Pap test every 3 
years until aged 75 years, independently to sexual activity. In older post-menopausal 
women the transformation zone may be difficult to see. The cervix is often much smaller 
and the amount of cervical cells found in the smears may be not optimal. We believe that 
two samples (one from the endocervix with cytobrush and one from ectocervix with Ayre 
spatule) and  smearing the cytological materials on two slides is the procedure of choice in 
order to obtain adequate material. 
5. Acknowledgments 
The authors thank Andrea Riolfatti and Suada Musabelliu for their help in the English 
translation, Beatrice Ferrari and  Giorgio Moretti for technical assistance. 
6. References 
ACS. American Cancer Society. Cervical cancer facts and figure. 2000.  
Ali-Fehmi R, Morris RT, Bandyopadhyay S, Che M, Schimp V, Malone JM Jr, Munkarah 
AR.Expression of cyclooxygenase-2 in advanced stage ovarian serous carcinoma: 
correlation with tumor cell proliferation, apoptosis, angiogenesis, and survival. Am 
J Obstet Gynecol. 2005; 192: 819-825. 
www.intechopen.com
Incidence of Invasive Squamous Cell Carcinoma Diagnosed With  
Opportunistic Screening in >70 Years-Old Women: Italy as a Case Study 
 
85 
Anttila A, Ronco G; Working Group on the Registration and Monitoring of Cervical Cancer 
Screening Programmes in the European Union; within the European Network for 
Information on Cancer (EUNICE). Description of the national situation of cervical 
cancer screening in the member states of the European Union. Eur J Cancer. 2009; 
45:2685-708. Epub 2009 Sep 8.   
Arbyn M, Antoine J, Mägi M, Smailyte G, Stengrevics A, Suteu O, Valerianova Z, Bray F, 
Weiderpass E. Trends in cervical cancer incidence and mortality in the Baltic 
countries, Bulgaria and Romania. Int J Cancer. 2011; 128:1899-907. 
Arbyn M, Anttila A, Jordan J, Ronco G, Schenck U, Segnan N, Wiener H, Herbert A, von 
Karsa L eds. European guidelines for quality assurance on cervical cancer 
screening. 2nd edition. Office for official publications of the European 
communities, Luxembourg 2008. 
Arbyn M, Autiere P, Ferlay J. Burden of cervical cancer in the 27 member states of the 
European Union: estimates for 2004. Ann Oncol 2007;18:1425–1431.  
Arbyn M, Rebolj M, De Kok IM, Fender M, Becker N, O'Reilly M, Andrae B. The challenges 
of organising cervical screening programmes in the 15 old member states of the 
European Union. Eur J Cancer. 2009 Oct;45(15):2671-8. Epub 2009 Aug 18.   
Baay MF, Tjalma WA, Weyler J, Pattyn GG, Lambrechts HA, Goovaerts G, Baekelandt M, 
Buytaert P, Van Marck EA, Lardon F, Vermorken JB. Prevalence of human 
papillomavirus in elderly women with cervical cancer. Gynecol Obstet Invest. 2001; 
52: 248-251. 
Bastos J, Peleteiro B, Gouveia J, Coleman MP, Lunet N. The state of the art of cancer control 
in 30 European countries in 2008. Int J Cancer. 2010; 126:2700-15. 
Bisset LR, Lung TL, Kaelin M, Ludwig E, Dubs RW. Reference values for peripheral blood 
lymphocyte phenotypes applicable to the healthy adult population in Switzerland. 
Eur J Haematol 2004; 72: 203–212. 
Bos AB, Rebolj M, Habbema JD, van Ballegooijen M. Nonattendance is still the main 
limitation for the effectiveness of screening for cervical cancer in the Netherlands. 
Int J Cancer 2006;119:2372-2375. 
Brinton LA, Schairer C, Haenszel W, Stolley P, Lehman HF, Levine R, Savitz DA. Cigarette 
smoking and invasive cervical cancer JAMA 1986; 255: 3265-3269. 
Buckley JD, Harris RW, Doll R, Vessey MP, Williams PT. Case-control study of the husbands 
of women with dysplasia or carcinoma  of the cervic uteri. Lancet 1981; 2: 1010-
1015. 
Carmichael JA, Clarke DH, Moher D, Ohkle ID, Karchmar EJ. Cervical carcinoma in women 
aged 34 and younger. Am J Obset Gynecol 1986; 66(Suppl): 82-85. 
Chakravarti B, Abraham GN. Aging and T-cell-mediated immunity. Mech Ageing Dev 1999; 
108: 183–206. 
Chin-Hong PV, Palefsky JM. Human papillomavirus anogenital disease in HIV-infected 
individuals. Dermatol Ther 2005; 18: 67–76. 
Chng WJ, Tan GB, Kuperan P. Establishment of adult peripheral blood lymphocyte subset 
reference range for an Asian population by single-platform flow cytometry: 
influence of age, sex, and race and comparison with other published studies. Clin 
Diagn Lab Immunol 2004; 11: 168–173. 
www.intechopen.com
Human Papillomavirus and Related Diseases 
– From Bench to Bedside – Research Aspects 
 
86
Cho Y, Gorina S, Jeffrey PD and Pavletich NP. Crystal structure of a p53 tumor suppressor-
DNA complex: understanding tumorigenic mutations. Science 1994; 265: 346-355. 
Choo KB and Chong KY Absence of mutation in the p53 and retinoblastoma susceptibility 
genes in primary cervical carcinomas. Virology 1993; 193: 1042-1046. 
Ciatto S, Grazzini G, Cecchini S, Iossa A. Screening history of incident cases of invasive 
carcinoma of the cervix. Tumori 1993; 79: 311–313.  
Clerici M, Merola M, Ferrario E, Trabattoni D, Villa ML, Stefanon B, Venzon DJ, Shearer 
GM, De Palo G, Clerici E. Cytokine production patterns in cervical intraepithelial 
neoplasia: association with human papillomavirus infection. J Natl Cancer Inst 
1997; 89: 245–250. 
Coleman D, Day N, Douglas G, Farmery E, Lynge E, Philip J, Segnan N. European 
guidelines for quality assurance in cervical cancer screening. Eur J Cancer 1993; 
29A (Suppl.4): 1-38. 
Commissione oncologica nazionale.Proposte operative in tema di prevenzione secondaria 
cervico-carcinoma uterino. In: Linee guida elaborate dalla Commissione oncologica 
nazionale, in applicazione di quanto previsto dal Piano Sanitario Nazionale per il 
triennio 1994-96, relativo all’azione programmata “Prevenzione e cura delle 
malattie oncologiche”, concernenti l’organizzazione della prevenzione e 
dell’assistenza in oncologia. Supplemento ordinario alla Gazzetta Ufficiale n.127, 1 
June 1996. 
Conferenza permanente per i rapporti tra lo Stato, le Regioni e le Province autonome di 
Trento e Bolzano. “Provvedimento 8 marzo 2001. Accordo tra il Ministro della 
sanità e le Regioni e Province autonome di Trento e Bolzano sulle linee-guida 
concernenti la prevenzione, la diagnostica e l’assistenza in oncologia”. Gazzetta 
ufficiale, 2 May 2001. 
Crook T and Vousden KH. Properties of p53 mutations detected in primary and secondary 
cervical cancers suggest mechanisms of metastasis and involvement of 
environmental carcinogens. EMBO J 1992; 11: 3935-3940. 
Crook T, Wrede D and Vousden KH. p53 point mutation in HPV-negative human cervical 
carcinoma cell lines. Oncogene 1991; 6: 873-875. 
De Jong A, van Poelgeest MI, van der Hulst JM, Drijfhout JW, Fleuren GJ, Melief CJ, Kenter 
G, Offringa R, van der Burg SH. Human papillomavirus type 16-positive cervical 
cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 
and E6. Cancer Res 2004; 64: 5449–5455. 
Devesa SS, Young JL Jr, Brinton LA, Fraumeni JF Jr. Recent trends in cervix uteri cancer. 
Cancer 1989; 64:2184 90. 
Di Bonito L. Cervical screening in Italy. Abstracts of the 35th European Congress of 
Cytology, Lisbon, Portugal, Sept. 27–30, 2009. Cytopatholology 2009;1:22.  
Douziech N, Seres I, Larbi A, Szikszay E, Roy PM, Arcand M, Dupuis G, Fulop T Jr. 
Modulation of human lymphocyte proliferative response with aging. Exp Gerontol 
2002; 37: 369–387. 
Eide TJ. Cancer of  the uterine cervix in Norway  by histologic type, 1970-84. J Natl Cancer 
Inst 1987; 79: 199-205. 
www.intechopen.com
Incidence of Invasive Squamous Cell Carcinoma Diagnosed With  
Opportunistic Screening in >70 Years-Old Women: Italy as a Case Study 
 
87 
F.X. Bosch, A. Lorincz and N. Munoz, Meijer CJ, Shah KV. The causal relation between 
human papillomavirus and cervical cancer, J Clin Pathol 2002; 55: 244–265.  
Ferlay J, Bray F, Pisani, Parkin DM (2001). Globocan 2000. Cancer Incidence, Mortality and 
Prevalence Worldwide. IARCPress: Lyon. 
Ferlay J, Bray F, Pisani, Parkin DM. GLOBOCAN 2002: Cancer incidence, mortality and 
prevalence worldwide. IARC Cancer base No.5, version 2.0. Lyon: IARC Press; 
2004. 
Fidler HK, Boyes DA, Worth AJ. Cervical cancer detection in British Columbia. A progress 
report . J Obstet Gynaecol Br Commonw 1968;75:392-404. 
Fujita M, Inoue M, Tanizawa O, Iwamoto S and Enomoto T. Alterations of the p53 gene in 
human primary cervical carcinoma with and without human papillomavirus 
infection. Cancer Res 1992; 52: 5323-5328. 
Garcia-Pineres AJ, Hildesheim A, Herrero R, Trivett M, Williams M, Atmetlla I, Ramirez M, 
Villegas M, Schiffman M, Rodriguez AC, Burk RD, Hildesheim M, Freer E, Bonilla 
J, Bratti C, Berzofsky JA, Pinto LA. Persistent human papillomavirus infection is 
associated with a generalized decrease in immune responsiveness in older women. 
Cancer Res. 2006; 66: 11070-11076. 
Giordano G, D'Adda T, Dal Bello B, Brigati F, Bersiga A, Campanini N, Berretta R, Rocco A, 
Merisio C. Clinicopathologic implications of the epidermal growth factor receptor, 
cyclooxygenase 2 expression, and human papillomavirus status in squamous cell 
carcinoma of the uterine cervix in the elderly. Int J Gynecol Cancer. 2011 Feb; 21: 
337-348. 
Green and A. Berrington de Gonzalez, Sweetland S, Beral V, Chilvers C, Crossely B, Deacon 
J, Hermon C, Jha P, Mant D, Peto J, Pike M, Vessey MP. Risk factors for 
adenocarcinoma and squamous cell carcinoma of the cervix in women aged 20–44 
years: the UK National Case-Control Study of Cervical Cancer, Br J Cancer 2003; 89: 
2078–2086. 
Hameed A, Fox WM, Kurman RJ, Hruban RH, Podack ER. Perforin expression in human 
cell-mediated luteolysis. Int J Gynecol Pathol 1995; 14: 151-157. 
Harris CC p53: At the crossroads of molecular carcinogenesis and risk assessment. Science 
1993; 262: 1980-1981. 
Helland A, Holm R, Kristensen G, Laern J, Kaern J, Karlsen F, Trope C, Nesland JM and 
Borresen AL. Genetic alterations of the p53 gene, p53 protein expression and HPV 
infection in primary cervical carcinomas. J Path 1993; 171:105-114. 
Hildesheim A, Wang SS. Host and viral genetics and risk of cervical cancer: a review. Virus 
Res 2002; 89: 229–240. 
Howell EA, Chen YT, Concato J. Differences in cervical cancer mortality among black and 
white women. Obset Gynecol 1999; 94: 509-515. 
Huang H, Patel DD, Manton KG. The immune system in aging: roles of cytokines, T cells 
and NK cells. Front Biosci 2005; 10: 192–215. 
Huibregtse JM, Scheffner M and Howley PM. Cloning and expression of the cDNA for E6-
AP, a protein that mediates the interaction of the human papillomavirus E6 
oncoprotein with p53. Mol Cell Biol; 1993; 13: 775-784. 
www.intechopen.com
Human Papillomavirus and Related Diseases 
– From Bench to Bedside – Research Aspects 
 
88
Janerich DT, Hadjimichael O, Schwartz PE, Lowell DM, Meigs JW, Merino MJ, Flannery JT, 
Polednak AP. The screening histories of women with invasive cervical cancer, 
Connecticut. Am J Public Health 1995; 85: 762–763.  
Jentsch-Ullrich K, Koenigsmann M, Mohren M, Franke A. Lymphocyte subsets' reference 
ranges in an age- and gender-balanced population of 100 healthy adults-A 
monocentric German study. Clin Immunol 2005; 116: 192–197. 
Jones WB, Shingleton HM, Russell A, Fremgen Am, Clive RE, Winchester DP, Chmiel JS. 
Cervical carcinoma and pregnancy. A national patterns of care study of the 
American College of Surgeons. Cancer 1996;77: 1479-1488. 
Kadish AS, Timmins P, Wang Y. Regression of cervical intraepithelial neoplasia and loss of 
human papillomavirus (HPV) infection is associated with cell-mediated immune 
responses to an HPV type 16 E7 peptide. Cancer Epidemiol Biomarkers Prev 2002; 
11: 483–488. 
Kam KM, Leung WL, Kwok MY, Hung MY, Lee SS, Mak WP. Lymphocyte subpopulation 
reference ranges for monitoring human immunodeficiency virus-infected Chinese 
adults. Clin Diagn Lab Immunol 1996; 3: 326–330. 
Kanda T, Watanabe S and Yoshiike K. Immortalization of primary rat cells by human 
papillomavirus type 16 subgenomic DNA fragment controlled by SV40 promoter. 
Virology 1988; 165: 321-325. 
Kenter GG, Schoonderwald EM, Koelma IA, Arentz N, Hermans J, Fleuren GJ. The 
cytological screening history of 469 patients with squamous cell carcinoma of the 
cervix uteri; does interval carcinoma exist? Acta Obstet Gynecol Scand 1996; 75: 
400–3. 
Kjellgren O. Mass screening in Sweden for cancer of the uterine cervix: effect on incidence 
and mortality . An overview. Gynecol Obset Invest 1986; 22: 57-63. 
Kuerbitz SJ, Plunkett BS, Walsh WV and Kastan MB Wild-type p53 is a cell cycle checkpoint 
determinant following irradiation. Proc Natl Acad Sci USA 1992;  89: 7491-7495. 
La vecchia C, Franceschi S, Decarli A, Gentile A, Fasoli M, Pampallona S, Tognoni G. 
Dietary vitamin A and the risk of invasive cervical cancer. Int J Cancer 1984; 34: 
319-322. 
Lee YY, Wilczynski P, Chumakov A, Chih D and Loeffler HP Carcinoma of the vulva: HPV 
and p53 mutations. Oncogene 1994; 9: 1655-1659. 
Lesack D, Wahab I, Gliks CB. Radiation-induced atypia of endocervical epithelium: a 
histological, immunohistochemical  and cytometric study. Int J Gynecol Pathol 
1996; 15: 242-247. 
Levi F, Lucchini F, Negri E, Franceschi S, La Vecchia C. Cervical cancer mortality in young 
women in Europe: patterns and trends. Eur J Cancer 2000; 36: 266-271. 
Lowe SW, Schmitt EM, Smith SW, Osborne BA and Jacks T. p53 is required for radiation-
induced apoptosis in mouse thymocytes. Nature 1993;  362: 847-849. 
Lugada ES, Mermin J, Kaharuza F, Ulvestad E, Were W, Langeland N, Asjo B, Malamba S, 
Downing R. Population-based hematologic and immunologic reference values for a 
healthy Ugandan population. Clin Diagn Lab Immunol 2004; 11: 29–34. 
www.intechopen.com
Incidence of Invasive Squamous Cell Carcinoma Diagnosed With  
Opportunistic Screening in >70 Years-Old Women: Italy as a Case Study 
 
89 
M. Walboomers, M.V. Jacobs and M.M. Manos, Bosch FX, Kummer JA, Shah KV, Snijders PJ, 
Peto J, Meijer CJ, Munoz N. Human papillomavirus is a necessary cause of invasive 
cervical cancer worldwide, J Pathol 1999; 189: 12–19.  
M.H. Schiffman, H.M. Bauer and R.N. Hoover RN, Glass AG, Cadell DM, Rush BB, Scott 
DR, Scherman ME, Kurman RJ, Wacholder S. Epidemiologic evidence showing that 
human papillomavirus infection causes most cervical intraepithelial neoplasia, J 
Natl Cancer Inst 1993; 85: 958–964.  
Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the 
biology and treatment of cancer. J Clin Oncol. 2003; 21: 2787-2799. 
Milde-Langosch KM, Albrecht K, Joram S, Schlechte H, Giessing M and Loning T. Presence 
and persistence of HPV infection and p53 mutation in cancer of the cervix uteri and 
the vulva. Int J Cancer 1995; 63: 639-645. 
Ministero della salute, Direzione generale della prevenzione. Screening oncologici. 
Raccomandazioni per la pianificazione e l’esecuzione degli screening di 
popolazione per la prevenzione del cancro della mammella, del cancro della cervice 
uterina e del cancro del colon retto. Roma, 2006. 
Miwa K, Miyamoto S, Imamura T, Nishida M, Yoshikawa Y, Nagata Y and Wake N. The 
role of p53 inactivation in human cervical cell carcinomadevelopment. Br J Cancer 
1995;  71: 219-226. 
Mubiayi N, Bogaert E, Boman F, Leblanc E, Vinarier D, Leroy JL, Querleu D. Cytological 
history of 148 women presenting with invasive cervical cancer [Article in French]. 
Gynaecol Obstet Fertil 2002; 30: 210–217.  
Munger K, Werness BA, Dyson N, Phelps WC, Harlow E and Howley PM. Complex 
formation of human papillomavirus E7 proteins with theretinoblastoma tumor 
suppressor gene product. EMBO J 1989;  8: 4099-4105. 
Nakagawa S, Watanabe S, Yoshikawa H, Taketani Y, Yoshiike K and Kanda T. Mutational 
analysis of human papillomavirus type 16 E6 protein: transforming function for 
human cells and degradation of p53 in vitro.  Virology 1992; 212: 535-542. 
Nakagawa S, Yoshikawa H, Jimbo H, Onda T, Yasugi T, Matsumoto K, Kino N, Kawana K, 
Kozuka T, Nakagawa K, Aoki M, Taketani Y. Elderly Japanese women with 
cervical carcinoma show higher proportions of both intermediate-risk human 
papillomavirus types and p53 mutations. Br J Cancer. 1999 Mar;79(7-8):1139-1144. 
NCI.SEER Cancer Statitics Review: 1973-1996. Bethesda, MD: National Cancer Institute; 
1999. 
Nevins JR E2F: A link between the Rb tumor suppressor protein and viral oncoproteins. 
Science 1992; 258: 424-429. 
Paquette RL, Lee YY, Wilczynski SP, Karmakar A, Kizaki M, Miller CW and Koeffler 
HP.Mutation of p53 and human papillomavirus infection in cervical carcinoma. 
Cancer 1993;  72: 1272-1280. 
Parkin DM , Nguyen-Dinh X Day NE. The impact of screening on the incidence of cervical 
cancer in England and Wales. Br J Obset Gynaecol 1985; 92: 150-157. 
Ratima K, Paul C, Skegg DC. Cervical smear history of Maori women developing invasive 
cervical cancer. NZ Med J 1993; 106: 519–521.  
www.intechopen.com
Human Papillomavirus and Related Diseases 
– From Bench to Bedside – Research Aspects 
 
90
Rodeck U, Jost M, Kari C, Shih DT, Lavker RM, Ewert DL, Jensen PJ.  EGF-R dependent 
regulation of keratinocyte survival. J Cell Sci. 1997; 110: 113-121. 
Ronco G, Giubilato P, Naldoni C Zorzi M, Anghinoni E, Scalisi A, Dalla Palma P, Zanier L, 
Barca A, Angeloni C, Gaimo MD, Maglietta R, Mancini E, Pizzuti R, Iossa A, 
Segnan N, Zappa M. Activity level and process indicators of organised 
programmes for cervical cancer screening in Italy. Epidemiol Prev 2006; 30 Suppl 1: 
27-40. 
Ronco G, Giubilato P, Naldoni C, Zorzi M, Anghinoni E, Scalisi A, Dalla Palma P, Zanier L, 
Barca A, Angeloni C, Gaimo MD, Maglietta R, Mancini E, Pizzuti R, Iossa A, 
Segnan N, Zappa M. Livello di attivazione ed indicatori di processo dei programmi 
organizzati di screening in Italia. In: Roselli Del Turco M, Zappa M. Osservatorio 
per la Prevenzione dei Tumori femminili. Terzo rapporto. Roma 2004: 38-51. 
Ronco G, Giubilato P, Naldoni C, Zorzi M, Anghinoni E, Scalisi A, Dalla Palma P, Zanier L, 
Barca A, Angeloni C, Gaimo MD, Maglietta R, Mancini E, Pizzuti R, Iossa A, 
Segnan N, Zappa M. Extension of organised cervical screening programmes in Italy 
and their process indicators. Epidemiol Prev 2007; 31 Suppl 2: 33-47. 
Ronco G, Pilutti S, Naldoni C, Pilutti S, Anghinoni  E, Zappa M, Dalla Palma P, Ciatto S, 
Segnan N. Stato dello screening cervicale in Italia. In: Rosselli Del Turco M, Zappa 
M eds. Osservatorio Nazionale per la Prevenzione dei Tumori femminili. Primo 
Rapporto. Roma 2002: 32-49. 
Ronco G, Ricciardi V, Naldoni C et al. Livello di attivazione ed indicatori di processo dei 
programmi organizzati di screening cervicale in Italia. In: Rosselli Del Turco M, 
Zappa M. Osservatorio Nazionale per la Prevenzione dei Tumori femminili. 
Secondo Rapporto. Roma 2003: 36-51. 
Ronco G, van Ballegooijen M, Becker N, Chil A, Fender M, Giubilato P, Kurtinaitis J, 
Lancucki L, Lynge E, Morais A, O'Reilly M, Sparen P, Suteu O, Rebolj M, Veerus P, 
Zakelj MP, Anttila A. Process performance of cervical screening programmes in 
Europe. Eur J Cancer. 2009; 45:2659-70. Epub 2009 Aug 25. 
Saito J, Hoshiai H, Noda K. Type of human papillomavirus and expression of p53 in elderly 
women with cervical cancer. Gynecol Obstet Invest. 2000; 49: 190-193. 
Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides 
and their receptors in human malignancies. Crit Rev Oncol Hematol. 1995; 19: 183-
232. 
Sansoni P, Cossarizza A, Brianti V, Fagnoni F, Snelli G, Monti D, Marcato A, Passeri G, 
Ortolani C, Forti E,. Lymphocyte subsets and natural killer cell activity in healthy 
old people and centenarians. Blood 1993; 82: 2767–2773. 
Sansoni P, Fagnoni F, Vescovini R, Mazzola M, Brianti V, Bologna G, Nigro E, Lavagetto G, 
Cossarizza A, Monti D, Franceschi C, Passeri M. T lymphocyte proliferative 
capability to defined stimuli and costimulatory CD28 pathway is not impaired in 
healthy centenarians. Mech Ageing Dev 1997; 96: 127–136. 
Santagostino A, Garbaccio G, Pistorio A, Bolis V, Camisasca G, Pagliaro P, Girotto M. An 
Italian national multicenter study for the definition of reference ranges for normal 
values of peripheral blood lymphocyte subsets in healthy adults. Haematologica 
1999; 84: 499–504. 
www.intechopen.com
Incidence of Invasive Squamous Cell Carcinoma Diagnosed With  
Opportunistic Screening in >70 Years-Old Women: Italy as a Case Study 
 
91 
Scheffner M, Werness BA, Huibregtse JM, Levine AJ and Howley PM. The E6 oncoprotein 
encoded by human papillomavirus types 16 and 18 promotes the degradation of 
p53. Cell 1993;  63: 1129-1136J. 
Shingleton HM, Orr JW. Cancer of the cervix: diagnosis and treatment. In: Monaghan J, Lind 
T, eds. Clinical obstretics and gynecology. New York: Churchill Livingstone; 1987. 
Smith JS, Green J, Berrington de Gonzales A, Appleby P, Peto J, Plummer M, Franceschi S, 
Beral V. Cervical cancer and use of hormonal contraceptives: a systematic review. 
Lancet 2003; 361: 1159-1167. 
Solomon D, Davey D, Kurman R, Moriarty A, O'Connor D, Prey M, Raab S, Sherman M, 
Wilbur D, Wright T Jr, Young N; The 2001 Bethesda System: terminology for 
reporting results of cervical cytology. JAMA. 2002;24;287:2114-2119. 
Song C, Vandewoude M, Stevens W, De Clerck L, Van der Planken M, Whelan A, Anisman 
H, Dossche A, Maes M. Alterations in immune functions during normal aging and 
Alzheimer's disease. Psychiatry Res 1999; 85: 71–80. 
StriFazzari M, Cu-Uvin S, Bacon M, Schuman P, Levine AM, Durante AJ, Gange S, Melnick 
S, Burk RD.ckler HD, Palefsky JM, Shah KV, Anastos K, Klein RS, Minkoff H, Duerr 
A, Massad LS, Celentano DD, Hall C . Human papillomavirus type 16 and immune 
status in human immunodeficiency virus-seropositive women. J Natl Cancer Inst 
2003; 95: 1062–1071. 
Stuart GC, Mc Gregor SE, Duggan MA, Nation JG. Review of the screening history of 
Alberta women with invasive cervical cancer. CMAJ 1997; 157: 513–519.  
Subbaramaiah K, Dannenberg AJ. Cyclooxygenase-2 transcription is regulated by human 
papillomavirus 16 E6 and E7 oncoproteins: evidence of a corepressor/coactivator 
exchange. Cancer Res. 2007; 67: 3976-3985. 
Tsegaye A, Messele T, Tilahun T, Hailu E, Sahlu T, Doorly R, Fontanet AL, Rinke de Wit TF. 
Immunohematological reference ranges for adult Ethiopians. Clin Diagn Lab 
Immunol 1999; 6: 410–414. 
Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells 
overexpressing prostaglandin endoperoxide synthase-2. Cell. 1995; 83: 493-550. 
Tsujii M, Kawano S, DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells 
increases metastatic potential. Proc Natl Acad Sci U S A. 1997; 94: 3336-3340. 
Tsukui T, Hildesheim A, Schiffman MH, Tsukui T, Hildesheim A, Schiffman MH,    Tsukui 
T, Hildesheim A, Schiffman MH, Lucci J 3rd, Contois D, Lawler P, Rush BB, 
Lorincz AT, Corrigan A, Burk RD, Qu W, Marshall MA, Mann D, Carrington M, 
Clerici M, Shearer GM, Carbone DP, Scott DR, Houghten RA, Berzofsky JA . 
Interleukin 2 production in vitro by peripheral lymphocytes in response to human 
papillomavirus-derived peptides: correlation with cervical pathology. Cancer Res 
1996; 56: 3967–3974. 
W.A. Tjalma, M. Arbyn, J. Paavonen, van Waes TR, Bogers JJ.  Prophylactic human 
papillomavirus vaccines: the beginning of the end of cervical cancer, Int J Gynecol 
Cancer 2004;14:751–761.  
Waterhouse J, Muir C, Stranmugaratnam K, Powell J. Cancer incidence  in five continent; 
Vol IV. IARC scientific  publication series, No.42. Lyon: IARC Press; 1982. 
www.intechopen.com
Human Papillomavirus and Related Diseases 
– From Bench to Bedside – Research Aspects 
 
92
Werness BA, Levine AJ and Howley PM. Association of human papillomavirus types 16 and 
18 E6 proteins with p53. Science 1990;  248: 76-79. 
Williams CS, DuBois RN. Prostaglandins endoperoxide synthase: why two isoforms? Am J 
Physiol. 1996; 270: 393-400. 
X.B. Trinh, J.J. Bogers, E.A. Van Marck and W.A. Tjalma. Treatment policy of 
neuroendocrine small cell cancer of the cervix, Eur J Gynaecol Oncol 2004;25; 40–44.  
Zucchetto A, Franceschi S, Clagnan E, Serraino D, Zanier L, Franzo A; Friuli Venezia Giulia 
Cancer Registry Working Group. Screening history of women with invasive 
cervical cancer in north-east Italy. Eur J Obstet Gynecol Reprod Biol. 2010; 152: 200-
204. 
www.intechopen.com
Human Papillomavirus and Related Diseases - From Bench to
Bedside - Research aspects
Edited by Dr. Davy Vanden Broeck
ISBN 978-953-307-855-7
Hard cover, 406 pages
Publisher InTech
Published online 25, January, 2012
Published in print edition January, 2012
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
Cervical cancer is the second most prevalent cancer among women worldwide, and infection with Human
Papilloma Virus (HPV) has been identified as the causal agent for this condition. The natural history of cervical
cancer is characterized by slow disease progression, rendering the condition, in essence, preventable and
even treatable when diagnosed in early stages. Pap smear and the recently introduced prophylactic vaccines
are the most prominent prevention options, but despite the availability of these primary and secondary
screening tools, the global burden of disease is unfortunately still very high. This book will focus on
epidemiological and fundamental research aspects in the area of HPV, and it will update those working in this
fast-progressing field with the latest information.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Teresa Pusiol (2012). Incidence of Invasive Squamous Cell Carcinoma Diagnosed with Opportunistic
Screening in >70 Years-Old Women: Italy as a Case Study, Human Papillomavirus and Related Diseases -
From Bench to Bedside - Research aspects, Dr. Davy Vanden Broeck (Ed.), ISBN: 978-953-307-855-7,
InTech, Available from: http://www.intechopen.com/books/human-papillomavirus-and-related-diseases-from-
bench-to-bedside-research-aspects/incidence-of-invasive-squamous-cell-carcinoma-diagnosed-with-
opportunistic-screening-in-70-years-old
© 2012 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
